Literature DB >> 3550340

The effects of delay in standard treatment due to induction chemotherapy in two randomized prospective studies.

R J Toohill, J A Duncavage, T W Grossmam, T C Malin, R W Teplin, J F Wilson, R W Byhardt, J S Haas, J D Cox, T Anderson.   

Abstract

It is often suggested that tumors will respond to induction chemotherapy and result in improved survival for patients with squamous cell carcinoma of the head and neck. Two regimens of induction chemotherapy were studied in separate randomized, prospective trials over the last 6 years. Eighty-three patients with advanced disease were entered into the first study (43/chemotherapy; 40/control), and 60 into the second (27/chemotherapy; 33/control). Patient randomization was stratified by stage (III/IV) and site (oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, paranasal sinuses). The first study utilized bleomycin, Cytoxan, methotrexate and 5-fluorouracil in two cycles (one cycle if no tumor response), followed by standard treatment which consisted of combined irradiation and surgery or, in some instances, primary irradiation alone. The second study utilized cisplatin and 5-fluorouracil in three cycles prior to standard treatment. An objective tumor response to chemotherapy was observed in 68% in the first study and 85% in the second. The patient survival in both studies (at 24 months in the first; at 19 in the second) was better in the control than that in the experimental groups (43% to 31%; 69% to 46%). In the second study, the average length of delay of standard treatment was longer than in the first study (95 days vs. 66 days; P less than .02). Results combining the P-values of both studies indicate that the relative risk of having persistent disease was 2.9 times greater for patients who received chemotherapy. While toxicity to chemotherapy was not a factor in survival, the number of patients who withdrew from the studies and those who did not comply with treatment were greater in the chemotherapy groups. Except for new drug regimens of exceptional promise, it is recommended that future studies be designed so that chemotherapy is given concurrent with, or following the completion of standard treatment.

Entities:  

Mesh:

Year:  1987        PMID: 3550340     DOI: 10.1288/00005537-198704000-00002

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

Review 1.  Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Authors:  Ambika Parmar; Michaelina Macluskey; Niall Mc Goldrick; David I Conway; Anne-Marie Glenny; Janet E Clarkson; Helen V Worthington; Kelvin Kw Chan
Journal:  Cochrane Database Syst Rev       Date:  2021-12-20

Review 2.  Current role of chemotherapy in head and neck cancer.

Authors:  J S Tobias
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

3.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.

Authors:  Benjamin Lacas; Alexandra Carmel; Cécile Landais; Stuart J Wong; Lisa Licitra; Jeffrey S Tobias; Barbara Burtness; Maria Grazia Ghi; Ezra E W Cohen; Cai Grau; Gregory Wolf; Ricardo Hitt; Renzo Corvò; Volker Budach; Shaleen Kumar; Sarbani Ghosh Laskar; Jean-Jacques Mazeron; Lai-Ping Zhong; Werner Dobrowsky; Pirus Ghadjar; Carlo Fallai; Branko Zakotnik; Atul Sharma; René-Jean Bensadoun; Maria Grazia Ruo Redda; Séverine Racadot; George Fountzilas; David Brizel; Paolo Rovea; Athanassios Argiris; Zoltán Takácsi Nagy; Ju-Whei Lee; Catherine Fortpied; Jonathan Harris; Jean Bourhis; Anne Aupérin; Pierre Blanchard; Jean-Pierre Pignon
Journal:  Radiother Oncol       Date:  2021-01-27       Impact factor: 6.280

4.  Evaluation of neo-adjuvant, concurrent and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma: a meta-analysis.

Authors:  Fahimeh Akhlaghi; Mohammad Esmaeelinejad; Amin Shams; Arsalan Augend
Journal:  J Dent (Tehran)       Date:  2014-05-31

5.  Induction chemotherapy in patients with resectable laryngeal cancer: A meta-analysis.

Authors:  Pei Gao; Liang Gong; Xuefeng Wang
Journal:  Mol Clin Oncol       Date:  2018-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.